Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

Article Clinical Neurology

Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

Nicholas J. Ashton et al.

Summary: This study compared the main blood phosphorylated tau immunoassays in a memory clinic population and found that several plasma p-tau biomarkers can be used as stand-alone biomarkers to detect Alzheimer's disease.

ALZHEIMERS & DEMENTIA (2023)

添加到收藏夹

Article Medicine, General & Internal

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

Nicholas J. Ashton et al.

Summary: CSF p-tau epitopes increase early in the development of AD pathology and are a primary candidate for detecting incipient Aβ pathology.

EBIOMEDICINE (2022)

添加到收藏夹

Article Clinical Neurology

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline

Michelle M. Mielke et al.

Summary: CSF phosphorylated tau 217 and p-tau181 have subtle differences in predicting Alzheimer's disease, CSF MSD p-tau181 and p-tau217 are associated with MCI risk among amyloid-positive individuals, and there are subtle differences in predicting cortical thickness.

ALZHEIMERS & DEMENTIA (2022)

添加到收藏夹

Article Clinical Neurology

N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases

Anniina Snellman et al.

Summary: The study develops new N-terminal-directed CSF total tau assays, which show increased levels ahead of standard t-tau in the Alzheimer's disease continuum, higher levels in patients with CJD or acute neurological diseases, and better potential as Alzheimer's disease blood biomarkers compared to Quanterix total tau.

BRAIN (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring

Nicholas J. Ashton et al.

Summary: Blood biomarkers indicative of AD pathology are altered in both preclinical and symptomatic stages of the disease. The findings suggest that p-tau217 could serve as a surrogate marker of disease progression, as it is associated with cognitive decline and brain atrophy.

NATURE MEDICINE (2022)

添加到收藏夹

Article Clinical Neurology

Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

Thomas K. Karikari et al.

Summary: Phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) is a biomarker for Alzheimer's disease (AD), and novel immunoassays targeting different fragments of p-tau provide better diagnostic accuracy for MCI-AD and AD dementia, especially in relation to A beta pathophysiology.

ALZHEIMERS & DEMENTIA (2021)

添加到收藏夹

Article Medicine, Research & Experimental

P-tau235: a novel biomarker for staging preclinical Alzheimer's disease

Juan Lantero-Rodriguez et al.

Summary: Alzheimer's disease has a long preclinical phase and requires biomarkers for early pathological changes. P-tau235 may be a key feature and staging biomarker. A new CSF p-tau235 assay shows promise in clinical research.

EMBO MOLECULAR MEDICINE (2021)

添加到收藏夹

Article Clinical Neurology

Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology

Nicholas J. Ashton et al.

Summary: Plasma phosphorylated tau231 is a promising biomarker for detecting Alzheimer's disease, accurately distinguishing AD patients from others and showing potential for early detection of pathology. Its performance is strong across various disease settings and it correlates well with other indicators of AD progression.

ACTA NEUROPATHOLOGICA (2021)

添加到收藏夹

Review Geriatrics & Gerontology

The Impact of Disease Comorbidities in Alzheimer's Disease

Jose A. Santiago et al.

Summary: Alzheimer's disease (AD) is often accompanied by a variety of other chronic diseases, including diabetes and cardiovascular disease, which may increase the risk of AD. Research suggests that disruption in several shared biological pathways could be the underlying mechanism for the association between AD and these comorbidities. Inflammation is considered a common dysregulated pathway shared by most comorbidities associated with AD.

FRONTIERS IN AGING NEUROSCIENCE (2021)

添加到收藏夹

Editorial Material Clinical Neurology